Article Text

CTAS: a CT score to quantify disease activity in pulmonary sarcoidosis
  1. Rachel Benamore1,
  2. Yvonne R Kendrick2,3,
  3. Emmanouela Repapi4,
  4. Emma Helm5,
  5. Suzanne L Cole3,
  6. Stephen Taylor4,
  7. Ling-Pei Ho2,3
  1. 1Thoracic Imaging Department, Churchill Hospital, Oxford, UK
  2. 2Oxford Interstitial Lung Disease Service, Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford, UK
  3. 3MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
  4. 4Computational Biology Research Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
  5. 5Radiology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
  1. Correspondence to Ling-Pei Ho, Oxford Interstitial Lung Disease Service, Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford OX3 7LJ, UK; Ling-pei.ho{at}


Background A major gap in the management of sarcoidosis is the lack of accessible and objective methods to measure disease activity. Since 90% of patients have pulmonary involvement, we explored if a disease activity score based on thoracic CT scans could address this clinical issue.

Methods High-resolution CT scans from 100 consecutive patients with sarcoidosis at a regional sarcoidosis service were scored for extent of CT abnormalities known to relate to granuloma or lymphocytic infiltration from published CT-pathological studies. These individual abnormality scores were then correlated against serum ACE, sIL-2R and change in FVC to identify CT abnormalities that reflect contemporaneous disease activity. The sum of these scores, or CT Activity Score (CTAS), was then validated against FVC response to treatment.

Findings CT extent scores for nodularity, ground-glass opacification, interlobular septal thickening and consolidation correlated significantly with at least one of the disease activity parameters and were used to form CTAS. CTAS was found to predict FVC response to treatment at 1 year and was highly reproducible between radiologists. An abbreviated CTAS (aCTAS), constructed from presence or absence of the four CT abnormalities, also showed significant correlation with FVC response to treatment. CTAS and aCTAS also correlated with response to treatment in the fibrotic subgroup.

Interpretation CTAS provides a concept for an objective and reproducible CT scoring method to quantify disease activity in sarcoidosis. The score can potentially be used to stratify patients according to disease activity, determine response to treatment and establish if fibrotic sarcoidosis is active.

  • Sarcoidosis
  • Imaging/CT MRI etc
View Full Text

Statistics from


  • RB and YRK are joint first authors.

  • Contributors YRK contributed to design, writing and analysis of data. RB scored the CT and contributed to design and discussions of the data. EH scored the second set of CTs and contributed to discussion of the manuscript. ER performed the statistical design, analysis and contributed to the design of the study. ST contributed to statistical analysis. SLC performed some of the serum analyses. L-PH conceived the idea, designed, analysed and wrote the paper.

  • Funding The study was funded by the NIHR Biomedical Research Centre at Oxford.

  • Competing interests None declared.

  • Ethics approval South Central National Research Ethics Service Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.